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Introduction: Over time, continuous flow ventricular assist devices (VADs) have 
become the primary form of implanted mechanical circulatory support (MCS) due 
to their smaller size, higher energy efficiency, longer durability, and fewer LVAD-
related complications when compared to pulsatile flow VADs.  However, 
continuous and pulsatile flows may elicit different cellular and tissue response, 
particularly in the arterial vasculature, which could have a profound impact on 
the future operation of MCS devices.  Therefore, a unique ex vivo perfusion 
system integrated with a mock adult circulatory system was design to study the 
impact of VAD-generated flow patterns on vascular function. 
 
Methods: The benefits of a mock circulatory loop and an ex vivo perfusion 
system were combined by designing and integrating a vessel perfusion chamber 
to an adult-sized mock circulatory loop as a parallel flow branch distal to VAD 
outflow.  Testing was conducted using a mock over several physiologic 
conditions (normal, heart failure, and hypertension) and at various levels of VAD 
flow.  The system was integrated into an incubator to allow for control of pH and 
temperature in future studies and fitted with a vessel for feasibility testing.  Data 
was collected using a custom Labview program and analyzed using the HEART 





Results: The chamber was successfully fabricated and installed in the mock 
circulatory system, allowing for perfusion and longitudinal stretching of bovine 
carotid arteries.  The waveforms and values for pressures and flows created in 
the mock loop were similar to physiologic values under each tested condition.  
Under normal hemodynamic conditions (CO = 4.5 L/min, MAP = 91 mmHg) 
perfusion chamber flow was 0.51 L/min, while under HF conditions (CO = 3.3 
L/min, MAP = 81 mmHg) it was reduced to 0.18 L/min, which are representative 
of in vivo carotid artery hemodynamics.  Due to physiologic preloads and 
afterloads, VAD performance was as would be expected in clinical application.  
The system was found to be sufficient for future testing with bovine carotid 
arteries and extended perfusion times (>24 hours). 
 
Conclusions:  This study resulted in an ex vivo vessel perfusion system that can 
successfully expose bovine carotid arteries to physiologic and VAD-specific 
hemodynamic waveforms.  The ability to combine the mock ventricle with 
clinically implanted VADs makes this system both unique and clinically relevant 
for studying the effects of continuous versus pulsatile flow on the peripheral 
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CHAPTER I – INTRODUCTION 
A. Heart Failure 
An estimated 5.1 million Americans over the age of 20 are currently living with 
heart failure6, while over 200,000 of that population have refractory end-stage 
heart failure with a mortality rate of 70% - 90%7.  That number is expected to 
increase by 25% by the year 2030. Cardiovascular disease is also costly, as it is 
projected to incur $358 billion in medical expenses in 2015, with that number 
climbing to $818.1 billion by 2030.  Congestive heart failure (CHF) alone 
accounts for $32.4 billion and $77.7 billion of those figures, respectively, or 
approximately 9% of the total cost.  These numbers indicate that CHF is a 
disease that warrants continued research and attention. 
CHF occurs when blood backs up in other areas of the body due to ineffective 
pumping of the heart8.  This ineffectiveness can result from systolic failure, when 
the heart is too weak to eject a sufficient volume of blood, or diastolic failure, 
when the cardiac muscle becomes stiff and does not fill with blood easily.  
Typically, CHF results from a combination of these deficiencies and thus prohibits 
the heart from delivering sufficient amounts of oxygen-rich blood to the body 
due to decreased pressures and compliances throughout the cardiovascular 
system. 
As CHF progresses, the body initiates a multitude of compensatory mechanisms 
in varying degrees.  The Frank-Starling mechanism allows the heart to change its 
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force of contraction and therefore stroke volume in response to venous return9.  
In CHF, this mechanism can have potentially adverse effects, leading to 
ventricular dilation and increased heartrate.  Several neurohumoral responses 
are also initiated, such as the activation of the sympathetic nerves, the renin-
angiotensin system of the kidneys, and increased release of antidiuretic hormone 
and atrial natriuretic peptide.  These mechanisms result in increased fluid 
retention and edema, leading to arterial vasoconstriction, venous constriction, 
and increased blood pressure.  
 
B. Treatment Options 
The most effective long-term remedy for CHF is a heart transplant.  
Unfortunately, less than 2,400 such procedures are performed in the United 
States each year due to a widespread shortage of available donor organs 
(Figure 1).  The number of annual heart transplants has been consistent for 
over 20 years, even in spite of the increasing HF diagnoses.  For the remaining 
end-stage HF patients who are unable to receive a transplant due to lack of 





Figure 1. Trends in heart transplantations in the U.S.6 
 
For patients suffering from New York Heart Association (NYHA) Class I and Class 
II heart failure, proper medical management is the first step in effectively 
managing its symptoms.  Two common classes of medications prescribed in the 
treatment of heart failure are inotropes and beta-blockers. Inotropes are used to 
alter the force of cardiac muscle contraction by either weakening the 
contractions (negative inotropes) or strengthening them (positive inotropes)10. 
Examples include epinephrine, norepinephrine, and dobutamine.  Beta-blockers 
reduce the workload on the heart and dilate your blood vessels, causing your 
heart to beat slower and with less force1.  These medications are often best used 
in combination and supplemented with diuretics and ACE inhibitors. 
When patients enter the NYHA Class III and IV stages of heart failure and proper 
medical management is not enough to combat their severe limitations in activity, 
mechanical circulatory support (MCS) must be considered.  The original form of 
MCS was the cardiopulmonary bypass (CPB) machine, in which a series of 
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external roller pumps takes over the heart’s blood-pumping function while the 
blood is simultaneously oxygenated extracorporeally.  Fully implantable devices 
known as ventricular assist devices (VADs) were later developed.  VADs provided 
more prolonged periods of MCS outside of the hospital. 
The first generation of VADs were introduced in the late 1970s and consisted of 
bulky, pneumatically driven pumps, such as the HeartMate XVE (Thoratec Corp., 
Pleasanton, CA) and the Novacor LVAD (Novacor Corp., Oakland, CA), that 
produced pulsatile flow (PF) patterns.  Like most VADs, these pumps were 
designed to supplement the function of a single ventricle, typically the left.    
Despite the restrictive size and associated risks with early generation PF VADs, 
clinical management of HF with these devices was largely successful and 
established VADs as an effective option for late-stage HF patients. 
This second generation of VADs, led by the HeartMate II (Thoratec Corp., 
Pleasanton, CA) and the HVAD (HeartWare, Inc., Framingham, MA), gained 
widespread clinical acceptance after the turn of the century due to their smaller 
pump size and driver size, increased reliability, and improved efficiency.  
Improvements on this technology have allowed for even smaller and less 
invasive devices to be developed.  Still other devices in development include the 
third generation of VADs, such as the HeartMate III (Thoratec Corp., Pleasanton, 
CA), that are CF but have the capability to produce PF through various 




C. Effects of VADs 
As previously mentioned, CF VADs have become the primary form of implanted 
MCS for several reasons.  First, their smaller size allows them to be more easily 
implanted in the thoracic cavity.  CF VADs have also demonstrated higher energy 
efficiency, longer durability, and fewer post-surgical LVAD-related complications 
when compared to their PF counterparts11.  However, the effects of continuous 
versus pulsatile flow on the body continue to be studied and could have a 
profound impact on future MCS device technologies. 
The effects of flow patterns can be seen on various levels of bodily organization, 
from the cellular level, to the vascular level, and finally to the level of organ 
systems and their interactions.  On a cellular level, pulsatile flow has been shown 
to reduce endothelial damage compared to nonpulsatile flow12 and possibly 
suppress the release of potentially harmful cyotkines13, 14.  Increased pulse 
pressure from pulsatile flow in baroreceptor units has been shown to decrease 
systemic vascular resistance15 and the frequency-dependent component of these 
baroreceptors can be altered during different hemodynamic conditions16  Studies 
also show that the endothelial release of nitric oxide, a key cellular component in 
cardiovascular function, in the peripheral vasculature is enhanced by pulsatile 
flow17.  
On a vascular level, the effects of critical shear stresses can be seen through the 
activation and manipulation of several different biological mechanisms within the 
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vasculature, which are induced by two types of mechanical stretch in the 
vessels18, 19.   These changes can have long term effects on endothelial-mediated 
vascular adaptive mechanisms20.  Moreover, nonpulsatile flow in a total artificial 
heart experiment has been shown to cause narrowing and rarefaction in the 
microcirculatory network, causing dystrophy in samples from the lungs, liver, and 
kidneys21.  
Those microcirculatory effects can lead to changes in end-organ behavior 
stemming from the varying flow patterns.  In the kidneys, short-term results 
seem to favor the use of pulsatile flow22, while long-term continuous flow obtains 
better renal perfusion than short-term usage and is not technically inferior to 
pulsatile flow 23.  Studies conducted on the liver show that pulsatile flow sustains 
total hepatic blood flow more effectively than continuous flow, due to the specific 
preservation of hepatic arterial and portal venous blood flow (attributed to 
prevention of hepatic arterial vasoconstriction)24.  Similar impact was reported in 
the neurological system, in that lower vascular resistance and higher flow rates 
were associated with pulsatile versus nonpulsatile flow23, 25. Studies conducted 
on the gastrointestinal (GI) system are concerning, where data has shown that 
continuous flow is significantly more likely to cause GI bleeding than pulsatile 
flow, with a near ten-fold incidence difference in some cases26.   
Among many others, these findings have driven a growing movement by 
researchers to determine whether pulsatility is truly needed in the human 
cardiovascular system and, if so, to what degree it is needed.  While studies are 
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being conducted to investigate the need for this pulsatility27, the VAD industry 
and engineers are preemptively developing PF algorithms for current and next-
generation CF VADs28.  In order to test the biologic responses to these highly-
specialized VAD flow patterns with adequate scientific rigor and accuracy, 
specialized flow simulation systems must be developed. 
 
D. Mock Circulatory Loops 
A common method of mimicking in vivo flow conditions for the study of various 
flow patterns and/or MCS devices is the mock circulatory loop.  These loops 
begin with a source of flow, typically a mock ventricle driven pneumatically or 
with a piston29. Compliance chambers for arterial and/or venous compliance 
adjustment are typically used30, along with some sort of adjustable resistance to 
account for systemic and pulmonary vascular resistance31. Connections are made 
via polypropylene or other plastic tubing.  While the components seem basic, 
mock circulatory loops can be modified via any number of components or 
configurations to study many different circulatory scenarios. 
Many mock loop systems are created in order to be able to adapt to test the 
various types of MCS devices32-37. Other systems are more complex and 
specified, such as those used to study a pediatric circulation38, 39 or the 
associated Norwood procedure40 and Fontan circulation41.  Still others are used 
to develop and verify the aforementioned pulsatile flow patterns produced by 
continuous flow VADs42-44.   
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This diversity and adjustability is one of the main advantages of mock circulatory 
systems. Not only can these systems be set up to mimic various types of 
circulation, but the compliance, resistance, preload, afterload, and other included 
parameters can be adjusted to create a multitude of different cardiovascular 
conditions, such as hypertension or heart failure. Devices ranging from VADs33, 
to TAHs43, to IABPs36 can be included, as well as other prostheses37. Fluids of 
varying viscosities, such as water, glycerol, or blood can be utilized to achieve 
desired viscosities. Mock circulatory loops enable the user to instantaneously 
change hemodynamic conditions and spare the lives of animals that would 
typically be experimented on, while also being more cost efficient and 
reproducible than said animal experiments.  
The biggest disadvantage of these systems is that they are only models, and 
assumptions must inherently be made and accounted for. However, systems with 
increased complexity are able to account for more variables and therefore can 
provide highly accurate models of natural hemodynamic conditions. 
One such system is the standard mock loop setup used by investigators at the 
Cardiovascular Innovation Institute (CII). The standard setup consists of a 
silicone left ventricle pneumatically driven by an external driver, aorta, arterial 
resistance and compliance, and venous reservoir.  These elements are connected 
using plastic tubing connectors and flexible ¾” silicone tubing.  Ventricular 
pressure, heart rate, resistances, and compliances can be adjusted to reproduce 
hemodynamic pressure and flow waveforms of the physiology of an adult human 
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in several distinct conditions: normal, heart failure, and hypertension.  Aortic and 
LVAD flows are measured using in-line and clamp Transonic Flow Probes 
(Transonic Systems, Ithica, NY), respectively.  Aortic and left ventricular 
pressures are measured using single-tipped Millar pressure catheters (Millar 
Instruments, TX).  One of two pneumatic ventricle drivers can be used (LB 
Engineering, Germany; Thoratec Corp., Pleasanton, CA).  These drivers enable 
the modification and adjustment of key parameters such as ventricle systolic and 
diastolic time periods and pressure, vacuum, and motor percentages.  
 
E. Ex vivo Perfusion Systems 
Ex vivo perfusion systems are another tool with a multitude of uses. As the name 
implies, these systems involve the perfusion of blood or another nutrient-rich 
substance throughout a group of cells, tissue, or an organ in an environment 
outside the body.  These systems come in a wide range of sizes, from smaller 
systems for the perfusion of cell cultures to large configurations for the perfusion 
of entire organs. 
Two transplanted organs that are often perfused are the lungs and kidneys.  
Lungs can be perfused for 4-6 hours prior to transplant45, often 
normothermically46, 47 and in combination with static cold preservation to remedy 
the effects of warm ischemia48. This ex vivo lung perfusion has proven to be an 
effective way to help separate ‘good’ lungs from a previously rejected pool to 
assist with the shortage of donor lungs49. Specific interest lies in the area of 
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donation after circulatory death46, 50. In terms of kidneys, simple systems of 
normothermic perfusion immediately prior to transplant have been effective after 
prolonged periods of static cold storage51.  Because of this success, perfusion of 
kidneys with various substances has been studied52, 53. Other ex vivo perfusion 
systems have involved liver REFs, cirrhotic tissue REF, mouse placentas REF, and 
even bone REF, among others54-61. 
It is not surprising that ex vivo perfusion systems for cardiovascular tissues are 
extensively used in scientific research. Specifically, researchers have developed 
various systems for the perfusion of hearts.  As with other organs, the primary 
focus is preparing hearts for transplant62, 63.  Some systems have utilized animal 
hearts in order to develop tools to assess the viability of hearts for transplant64-
67.  While different parameters for evaluating the potential hearts are being 
determined68, 69, the effects of various parameters on the peripheral vasculature 
are also being examined. 
Like all ex vivo perfusion systems, these vascular perfusion systems can also vary 
widely in size, beginning with smaller microfluidic systems used for the perfusion 
of vascular endothelial cell cultures.  These types of systems are useful for 
identifying the effects of pulse waves on a cellular level and use similar 
components to mock circulatory loops, such as pulsatile blood pumps and flow 
meters70.  Unfortunately, these systems can typically only study a specific cell 
type, as opposed to the effects of flow on an entire vessel or organ. 
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More advanced systems attempt to mimic vessels by culturing vascular cells in 
flexible rubber tubing71, 72.  These systems are able to moderate shear stress 
levels72 and even mimic disease states71, but are unable to generate physiologic 
waveforms or waveforms associated with pathologic conditions.  Additional 
systems are also able to produce pulsatile flow patterns, but only incorporate 
static cell cultures and have issues with retrograde flow and shear stress and 
strain measurements73, 74.  
Similar to static culture protocol,  ex vivo perfusion of blood vessels requires 
them to be cultured at physiologic temperature and pH, and with appropriate 
culture medium with antibiotic and antifungal agents, with the added parameter 
of being exposed to various flow patterns.  Systems are typically driven via 
peristaltic pumps75-78 in order to mimic various pulsatile flow waveforms.  They 
typically utilize precise pressure, flow, and gas exchange control to measure a 
variety of endpoints, such as fluid mechanical forces75, 76 and biological marker 
expression78-82.  Some even have unique abilities like the capacity for longitudinal 
stretch77, 79 or the measurement of vessel diameter80, 83.  Like mock circulatory 
loops, these systems are highly adaptable and can be modified to support a 
variety of research needs. 
 
F. Purpose of the Research 
Although the effects of mechanical stimulation to the vasculature have been 
extensively studied, the response to CF VAD-generated continuous flow and 
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pulsatile flow profiles has not been examined. This project combines the 
advantages of a mock circulatory loop with those of an ex vivo perfusion by 
attaching a vessel within the mock loop and exposing it to those unique flow 
profiles.  By mimicking the complexity of the physiologic in vivo environment by 
using the combination of a pneumatic ventricle and VAD in series, this system is 
capable of providing valuable information on the effects of continuous and 
pulsatile flow on the peripheral vasculature. 
The ex vivo perfusion system in this project will be able to accept a bovine 
carotid artery in order to accurately mimic in vivo conditions.  The chamber will 
be able to be integrated into a mock adult circulatory flow loop, and the system 
will include design features for temperature control, pH regulation, media 
exchange, and sterilization.   
The research performed in this thesis project accomplishes several aims. An ex 
vivo perfusion chamber is designed and integrated into the mock loop to prove 
feasibility of the system. Physiologic, pathologic, and mechanically-altered 
hemodynamics are created. Finally, the mock circulation system is reduced and 
re-designed for tissue culture considerations.  In addition, improvements to the 
perfusion chamber are presented, which are ready for fabrication and 
implementation with future studies. 
The vessel chamber for the artery is watertight, with cannulas at each end to 
attach the vessel and three ports for fluid exchange, ventilation, and proper gas 
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exchange.  The system is adjustable in length to allow for proper vessel 
stretching and is completely sterilizable.  
Once the chamber was completed, the mock circulatory loop was modified for 
integration of the perfusion system in order to demonstrate that physiologic 
flows and pressures can be achieved.  First, the chamber was integrated with 
only the mock ventricle to demonstrate normal physiologic pressures and flows.  
The CF VAD (HVAD, HeartWare Corp., Framingham, MA) was then added to 
demonstrate typical flows of the VAD in conjunction with the native ventricle. 
Finally, the pulsatile flow algorithm was implemented and data was collected.  
The mock loop system was then transferred to an incubator to achieve 














CHAPTER II – MATERIALS AND METHODS 
 
A. Ex vivo Vessel Perfusion Chamber 
The ex vivo vessel perfusion chamber was created using a 100 mL syringe of 
inner diameter 1.4 inches.  The tip was first cut off to create a hollow tube of 
length 4.8 inches. Three holes were drilled in the side of the tube: two to allow 
for fluid recirculation and one to vent.  Luer lock ports were then fixed in each 
hole and capped.  The handles of two syringe plungers were then removed so 
that only the rubber end was intact.  A hole was drilled in each plunger to allow 
for the insertion of a ¼” to 3/16” plastic tubing connector.  One end of each 
connector was connected externally to ¼” silicone tubing, while the end on the 
inside of the chamber was connected to the vessel.  Because no actual vessels 
were used in this study, a piece of 3/16” tubing was used to simulate the vessel 
for the preliminary design.  In hemodynamic verification studies, a section of 
penrose drain was used, as it better mimicked the elasticity of a natural vessel.  




Figure 2. Prototype of vessel perfusion chamber 
 
B. Mock Circulatory Loop 
 
For the purpose of this study, several modifications were made to the standard 
mock circulatory system to allow for testing of the carotid artery.  The ex vivo 
vessel perfusion chamber with the mock carotid artery, as described in the next 
section, was placed in a looped branch after the proximal compliance chamber.  
While a connection of the branch between the arterial and venous sides was 
considered, as this would be more physiologically accurate, the resulting system 
would likely require an additional compliance chamber and fluid reservoir, adding 
to the overall complexity of the system.  A second compliance chamber was 
added to represent the additional compliance of the carotid artery branch.  The 
remainder of the system remained physically unchanged.  An additional clamp 
Transonic Flow Probe (Transonic Systems, Ithica, NY) was placed just promixal 
to the vessel chamber to measure carotid artery pressure and an additional 
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single-tipped Millar pressure catheter (Millar Instruments, TX) was placed just 
distal to the chamber to measure carotid artery flow. A block diagram of the 
system can be seen in Figure 3, as well as the complete setup in Figure 4. 
  
Figure 3. Block diagram of modified mock circulatory loop with components: A. 
pneumatic ventricle, B. VAD, C. proximal compliance, D. vessel chamber, E. distal 





Figure 4.  Complete setup of modified mock circulatory loop 
One of the key advantages of this ex vivo arterial perfusion system is the ability 
to integrate various MCS devices into the circulation, including several types of 
LVADs and counter-pulsation devices.  For the purposes of this study, the LVAD 
used was the centrifugal flow HVAD by HeartWare (Miami Lakes, FL).  For the 
first portion of the experiment, the standard controller was used to provide 
continuous flow to the system.   
However, the second portion of the experiment involved the use of a pulsatile 
flow algorithm for the pump.  For this purpose, a controller was programmed by 
engineers at HeartWare under the direction of the investigators to enable LVAD 
pump speed modulation (Figure 5).  The program enabled the user to alter the 
degree of pulsatility by changing three parameters: the change in RPM 
(amplitude), the time period, and the time interval between pulses.  This 
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controller allowed for the creation of pulsatile waveforms from the continuous 
flow HVAD to test the carotid artery under various flow conditions. 
 
Figure 5. Screenshot of HVAD pulsatility controller 
 
C. Incubator Integration 
For additional testing, the mock circulatory system was integrated into the 
incubator (Isotemp, Fischer Scientific) in order to prepare the system for testing 
under physiologic pH and temperature with actual carotid arteries.  The lack of 
space in the interior made some slight modifications necessary, including the 
shortening of tubing lengths and the fixation of the fluid reservoir at a fixed 
height.  A new fluid reservoir was also fabricated from a shallow plastic bin to 
allow it to be placed on the top shelf of the incubator. The complete setup can 
be seen in Figure 6 and a full schematic is attached in Appendix A. Once 
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integrated, data sets were collected at the same physiologic conditions as the 
initial testing to demonstrate similar performance of the system in its new 
configuration. 
 
Figure 6. Incubator testing setup 
 
D. Testing 
After the creation of the vessel chamber, testing was conducted using the 
aforementioned mock circulatory system.  First, data was collected under normal 
physiologic conditions without the inclusion of the HVAD.  This data was 
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collected at varying levels of pressure and flow in an attempt to match target 
values and waveforms (Table 1). The HVAD was then included and data sets 
were collected for heart failure and hypertension conditions at the following 
levels of VAD flow: no flow, low flow, medium flow, and high flow.  Low flow was 
defined as 2000 rpm.  High flow was defined as 3200 rpm according to the high 
rpm setting used clinically by physicians associated with the CII.  Medium flow 
was then taken as the midway point between low and high flow, 2600 rpm. The 
heart failure condition was created by increasing the compliance to reduce pulse 
pressures and decreasing the drive pressure and increasing the preload to 
simulate a dilated left ventricle and increase left ventricular end-diastolic 
pressure.  The hypertensive condition was created by increasing resistance and 
decreasing compliance to simulate stiffening of the arteries. 
Table 1. Target blood pressures for hemodynamic states1-5.  Values without 
literature references were extrapolated from known values in other conditions. 
Hemodynamic 
Condition 
AoP (mmHg) CdAP (mmHg) CdAF 
(L/min) 
AoF 
(L/min) Systolic Diastolic Pulse Systolic Diastolic Pulse 
Normal 120 76 44 100 65 35 0.24 - 0.66 4.70 
Heart Failure 97 60 37 81 51 30 0.17 - 0.49 3.50 
Hypertension  >140 > 90 50 > 117 > 77 40 0.15 - 0.42 3.00 
 
In the second round of testing, after integration into the incubator, additional 
levels of flow were added.  A ‘full flow’ VAD condition set at 3800 rpm was added 
in an attempt to significantly reduce any remaining pulse pressure and 
completely unload the ventricle.  Prior to the administration of pulsatile flow 
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algorithms, a modified heart failure condition was created to match the exact 
parameters used in previous work84. Pulsatile flow algorithms at 2900 +/- 1100 
rpm and 3200 +/- 800 rpm were then added.  As detailed previously85, the first 
condition allowed for the maximum rpm modulation, while the second condition 
provided full unloading of the ventricle.  These two conditions were run both 
asynchronously at periods of 0.4, 0.5, 0.8, and 1.6 seconds and synchronously.  
In order for this to be accomplished, the cardiac cycle on the ventricle driver was 
set at 0.8 seconds and at 0.79 seconds on the VAD controller. This allowed the 
VAD to drift from phases of co-pulsation to counter-pulsation over a two minute 
data set.  Co-pulsation occurs when the VAD produces flow at the same time the 
ventricle is contracting, whereas counter-pulsation occurs when the VAD 
produces flow when the ventricle is filling.  The difference can be observed in the 
offset between the pulses of the aortic and left ventricular pressures.  In co-
pulsation, a zero degree offset exists between the pulses, whereas a 180 degree 
offset exists in counter-pulsation. 
In the final round of testing, a bovine carotid artery (1/8” diameter) was 
incorporated into the system (Figure 7) in the vessel perfusion chamber to 
prove feasibility of the system.  No vessel viability testing was conducted, but 
similar conditions as in the first two testing sets were replicated.  Specifically, 
baseline normal and heart failure conditions were established, followed by 




Figure 7. Bovine carotid artery integrated into vessel perfusion chamber 
 
E. Data Collection and Analysis 
Data was collected using a custom Labview program designed by investigators at 
the CII.  This program allows for the display of up to 9 pressures and flows and 
the acquisition of data sets of any size.  In this study, the parameters recorded 
were left ventricular pressure, aortic pressure, carotid artery pressure, aortic 
flow, VAD flow, and carotid artery flow.  Data sets of 15 or 30 seconds in length 
were acquired during bench top testing and for the basic hemodynamic and CF 
VAD conditions in incubator testing.  For the asynchronous pulsatile VAD flow 
modulation data sets, data sets ranging from 12 – 48 seconds were taken in 
order to record 15 ‘beats’ of the VAD.  For synchronous VAD data sets, data sets 
of two minutes were taken in order to record periods of both co-pulsation and 
counter-pulsation.  Prior to the commencement of each data set, the circulatory 
loop was run for 20 – 30 seconds to achieve a steady state for each condition.  
The data was analyzed using the HEART program, an automated beat-to-beat 
cardiovascular analysis package using Matlab86, along with additional custom 
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Matlab programs developed for the analysis of pulsatile VAD waveforms85.  This 
beat analysis allowed for the calibration of data channels, the calculation of 
various peaks, averages, and pulses, and the creation of data plots. Four second 





















CHAPTER III – RESULTS 
 
A. Bench Top Testing Results 
Initial testing of the ex vivo arterial perfusion system was successful in 
replicating physiologic and pathologic (heart failure and hypertension) waveforms 
for various pressures and flows.  Target pressure and flow parameters are listed 
in Table 1.  Resistance, compliance, and ventricle driver settings were first 
adjusted to create a baseline condition (no VAD) representing normal 
cardiovascular parameters (Figure 8).  It should be noted that large spikes in 
pressure and flow will appear due to ringing of the mechanical aortic and mitral 
valves.  Baseline aortic flow (AoF) was kept at approximately 4.0 L/min to 
represent a normal cardiac output.  Normal average pressures of 95 mmHg for 
AoP and 86 mmHg for CdAP were also obtained.  The baseline condition was 
followed by data sets of low, medium, and high VAD flow to verify proper 




Figure 8. Baseline pressures 
Next, a heart failure condition was created.  At the onset of the heart failure 
condition, left ventricular end-diastolic pressure rose (Figure 9).  This resulted in 
an overall decrease in pressures.  Mean AoF decreased to 3.3 L/min, while mean 
CdAF decreased to 0.18 L/min. 
 
Figure 9. Pressures in heart failure condition 
































































Similar to the hypertensive condition, pressures and flows increased with 
increasing VAD support until the ventricle became fully unloaded (Figure 10).  
However, AoF dropped below zero due to the elimination of flow through the 
aortic valve with increased ventricular unloading along with some slight 
retrograde flow due to the mock loop setup (Figure 11). 
 
Figure 10. Pressures in heart failure condition with high VAD flow 
 


































Figure 11. Flows in heart failure condition with high VAD flow 
 
After an additional baseline condition was created to restore normal function, a 
hypertensive condition was created (Figure 12).  This resulted in higher 
pressures, including higher pulse pressures for the aorta and carotid artery, 
caused in vivo by the stiffening of the vascular walls.  Due to the increased 
resistance, mean AoF was decreased to approximately 3 L/min and mean CdAF 
to 0.12 L/min, values that were slightly below literature references (Table 2).  

























Figure 12. Pressures in hypertensive condition 
Again, data sets of low, medium, and high VAD flow were taken to simulate VAD 
function in a hypertensive condition.  Pressures increased, likely due to the 
increased flow through the vessels (Figure 13), as the major hemodynamic 
effect of VAD support is increased pressure and flow87.  Mean AoF decreased 
with increasing VADF as more of the flow bypassed the aortic valve and went 
through the VAD and the ventricle became increasingly unloaded (Figure 14). 


































Figure 13. Pressures for hypertensive condition with high VAD flow 
 
Figure 14. Flows for hypertensive condition with high VAD flow 
In terms of the behavior of the carotid artery branch, the perfusion system was 
able to attain pressure and flow values near the target values.  While the values 
for the maximum and average carotid flows and pressures were able to be 
























































obtained (Table 2), waveform morphology for the CdAF differed slightly from 
published figures4, 88, 89.   
Table 2. Carotid artery pressures and flows in bench top testing versus target 
values. Values were obtained from figures due to influence of valve ringing in 
data analysis.  Bolded values fall within 10% sensor error range of target values. 
 
Target Values Obtained Values 
Hemodynamic 
Condition 
CdAP (mmHg) CdAF 
(L/min) 
CdAP (mmHg) CdAF 
(L/min) Systolic Diastolic Pulse Systolic Diastolic Pulse 
Normal 100 65 35 0.24 - 0.66 98 69 29 0.20 
Heart Failure 81 51 30 0.17 - 0.49 85 59 26 0.18 
Hypertension  > 117 > 77 40 0.15 - 0.42 140 100 40 0.12 
 
 
B. Incubator Testing Results 
Once the ex vivo arterial perfusion system was transferred from the bench top to 
the incubator, the first goal of testing was to reestablish proper pressure and 
flow waveforms for baseline, heart failure, and hypertensive hemodynamic 




Figure 15. Pressures in baseline condition 
 
Figure 16. Pressures in heart failure condition 

































































Figure 17. Pressures in hyptertensive condition 
After each of these basic conditions were established, four levels of VAD support 
were tested under each condition.  The three levels used in the initial testing 
were replicated along with the addition of the aforementioned ‘full VAD’ 
condition, in which the VAD was set to 3800 rpm in order to fully unload the 
ventricle and reduce or eliminate any pulse pressures.  As expected and 
observed in the initial testing, the pulse pressures were reduced as the level of 
CF VAD support increased to full ventricular unloading (Figure 18). However, 
they still remained slightly higher than the pulse pressures that have been 
observed in clinical VAD patients, which can drop as low as 3 – 5 mmHg, 
although pulse pressures are often kept between 10 – 20 mmHg in optimal VAD 
use87.  


































Figure 18. Pulse pressures (mmHg) in incubator testing with increasing CF VAD 
support 
While carotid artery pressures were similar to those from the initial testing, a 
calibration error led to negative readings for the carotid artery flows.  While the 
flows were negative, they still showed similar amplitude and waveform 
morphology as those in previous testing.  The error was remedied for the final 
round of testing and proper flows were achieved. 
Table 3. Carotid artery pressures and flows in incubator testing versus target 
values. Values were obtained from figures due to influence of valve ringing in 
data analysis. Bolded values fall within 10% sensor error range of target values. 
 
Target Values Obtained Values 
Hemodynamic 
Condition 
CdAP (mmHg) CdAF 
(L/min) 
CdAP (mmHg) CdAF 
(L/min) Systolic Diastolic Pulse Systolic Diastolic Pulse 
Normal 100 65 35 0.24 - 0.66 99 69  30 -0.29 
Heart Failure 81 51 30 0.17 - 0.49  87 66   21 -0.38 
































As one of the primary advantages of this system is its ability to create a 
multitude of VAD-specific waveforms, a laptop fitted with a VAD pulsatility 
program was then connected to the system as the VAD controller.  Prior to the 
VAD pulsation data sets, an altered heart failure state was created to match the 
state established by Ising in previous research85.  As detailed in the previous 
section, the VAD was pulsed asynchronously and synchronously at varying time 
periods and levels of rpm modulation. In the asynchronous mode, unique, yet 
inconsistent waveforms can be produced when the asynchronous timing 
produces high degrees of variability in pulse pressure (Figure 19). In the 
synchronous mode, the VAD support drifted from periods of co-pulsation (Figure 
20) to counter-pulsation (Figure 21).   
 
Figure 19. Pressures in asynchronous VAD operation at 3200 +/- 800; cycle 
time 3.2 seconds 


































Figure 20. Synchronous co-pulsation at 3200 +/- 800 rpm; cycle time 0.795 
seconds 
 
Figure 21. Synchronous counter-pulsation at 3200 +/- 800 rpm; cycle time 
0.795 seconds 
In the clinical context, the ultimate goal of these algorithms is to increase 
pulsatility in the peripheral vasculature, which can be measured by the 




























































calculation of AoP and CdAP pulse pressures.  In the experimental context, these 
tests were performed to demonstrate that the ex vivo system could create 
complicated VAD-specific hemodynamic waveforms in the presence of a mock 
left ventricle and with the potential to support artery perfusion. The results in the 
incubator setup show that, particularly in the synchronous co-pulsation mode of 
operation, as the 180 degree offset of the pulses in counter-pulsation mode 
produces destructive interference and results in a near continuous signal.  The 
co-pulsation synchronous mode is able to show near-physiologic aortic pulse 
pressures, while the counter-pulsation synchronous mode exhibits low aortic 
pulse pressures.  The asynchronous mode of pulsatile VAD flow delivers a 
variable pulse pressure from beat to beat, which is still greater than pulse 
pressures provided on full CF VAD support.  These compare to a pulse pressure 
of approximately 10 mmHg at a continuous VAD output of 3200 rpm (Figure 
22).  It should be noted that the low pulse pressure during asynchronous 
pulsation at 3200 +/- 800 rpm with a pulse width of 0.4 seconds is due to the 
timing of the pulses, which happened to occur in exact counter-pulsation to the 
pulses of the ventricle, minimizing pulse pressure as in synchronous counter-




Figure 22. Pressures at full VAD support in Heart Failure condition 
Table 4. Pulse pressures in pulsatile mode of VAD operation during incubator 
testing 
Mode rpm Δt AoP Pulse 
Asynchronous 
2900 +/- 1100 0.4 36 
2900 +/- 1100 0.5 39 
2900 +/- 1100 0.8 56 
2900 +/- 1100 1.6 102 
3200 +/- 800 0.4 6 
3200 +/- 800 0.5 44 
3200 +/- 800 0.8 50 
3200 +/- 800 1.6 85 
Sync Co-pulse 
2900 +/- 1100 0.3975 35 
3200 +/- 800 0.3975 33 
Sync Counter-pulse 
2900 +/- 1100 0.3975 9 






































C. Vessel Testing Results 
Baseline normal (Figure 23) and heart failure (Figure 24) conditions were 
again established, followed by CF VAD conditions at low, medium, high, and full 
VAD flow.  Trends in flow and pressure in these conditions were normal and 
matched previous testing results (Figure 25).  
 
Figure 23. Pressures in normal condition during vessel testing 


































Figure 24. Pressures in heart failure condition during vessel testing 
 
 Figure 25. Change in CdAP with increasing VAD flow in heart failure condition 
Once those conditions were replicated, data sets of pulsatile VAD flow were 
taken both asynchronously and synchronously, with both counter-pulsation and 
co-pulsation being achieved.  Pulse pressures in the VAD pulsatility data sets 
were similar to those previously recorded (Table 4), while all carotid artery flows 






















































and pressures matched their target values (Table 5).  All other data from the 
vessel testing can be found in Appendix C.  
Table 5. Carotid artery pressures and flows in vessel testing versus target 
values.  Values were obtained from figures due to influence of valve ringing in 
data analysis.  Bolded values fall within 10% sensor error range of target values. 
 
Target Values Obtained Values 
Hemodynamic 
Condition 
CdAP (mmHg) CdAF 
(L/min) 
CdAP (mmHg) CdAF 
(L/min) Systolic Diastolic Pulse Systolic Diastolic Pulse 
Normal 100 65 35 0.24 - 0.66 102 68 34 0.46 
Heart Failure 81 51 30 0.17 - 0.49 86 56 30 0.29 
 
D. Shear Stress Calculations 
As previously mentioned, shear stresses in vessels have profound effects on a 
wide variety of vascular response mechanisms71-73, 90-101.  Therefore, shear 
stresses were calculated from the obtained volumetric flow measurements, per 
the methods utilized by Estrada et al91.  First, the kinematic viscosity of the fluid 
solution used was calculated using equation (1):   
     
 
 
   (1) 
Normosol-R, a a sterile, nonpyrogenic isotonic solution of balanced electrolytes in 
water102, was used as the fluid solution in order to provide the slight increase in 
viscosity over water needed for HVAD operation.  Its density was assumed to be 
1,010 kg/m3, between the densities of water and blood plasma103.  Likewise, the 
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dynamic viscosity was assumed to be 1.10 cP to lie between those of water and 
blood plasma104.  Because of their low dynamic viscosities, water and plasma are 
assumed to be Newtonian fluids whose viscosity is not dependent upon flow 
rate105.  Therefore, Normosol-R is also assumed to be a Newtonian fluid.  To 
characterize the flow, the dimensionless Reynold’s number was then obtained 
using equation (2):  
   
   
  
   (2) 
 
The volumetric flow rate, Q, was attained from the CdAF flow sensor.  The 
hydrodynamic diameter, DH, for a cylindrical tube is simply the diameter of the 
tube, and A is the cross-sectional area.  The calculation resulted in a value of 
1,074, indicating laminar flow.  Next, to evaluate the ratio of pulsatile flow 
frequency to viscous effect, the Wormersly Number was calculated using 
equation (3): 
    √
   
 
   (3) 
The pulsatile frequency, f, was taken as 1.167 Hz for the heart rate of 70 bpm 
used in most data sets.  Similarly to the hydrodynamic diameter, the 
hydrodynamic radius, RH, is merely the radius of the tube.  A value of 8.238 was 
obtained, indicating that the pulse frequency is sufficiently low that a parabolic 
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velocity profile develops during each cycle and is a good approximation to 
Poiseiulle Flow91.  Because of this, the shear stress could be estimated using 
equation (4): 




   
   
   (4)91 
The radius of the carotid artery channel is represented here as r.  Using this 
equation, the shear stresses for each hemodynamic condition were calculated 
and plotted using Matlab (Figure 26).   
 
Figure 26. Fluid shear stresses as a function of flow for each hemodynamic 
condition in initial testing 
These shear stresses are slightly higher (~10 dynes/cm2) than those in previous 
literature that closely match clinical values91.  However, they do follow a similar 
trend where the maximum shear stresses for the normal and heart failure 







































conditions are approximately 5-10 dynes/cm2 higher than in heart failure.  
Average values are not presented, as they are skewed due to the influence of 





















CHAPTER IV – CONCLUSIONS 
 
A. Limitations 
While the system has major advantages over others in literature, it is not without 
its limitations.  First and foremost, there are inherent limitations associated with 
mock circulatory systems.  The mechanical valves cause a ringing effect on the 
AoP and CdAP, while also having some effect on the LVP waveform.  If there 
effects were considered to be detrimental, the inclusion of tissue valves in the 
system may remedy some of these effects. 
The choice of the incubator for tissue preservation severely constrains the space 
for the system.  However, the majority of the components were able to fit inside. 
The only exception is the volume reservoir, which required some slight 
modifications. In the end, the data shows that this limitation was overcome, as 
the pressure and flow waveforms from the bench top testing were matched in 
the incubator testing.  Expansion of the current system would be difficult given 
the space constraints of the incubator. 
Finally, two limitations specific to the perfusion chamber are vessel loading and 
throughput.  The two unconstrained plungers could cause the vessel to twist and 
tear in loading, so a more sophisticated loading system is desirable.  Also, the 
single vessel system provides low throughput, although a multiple vessel system 
is not feasible due to greatly increased complexity to the system and the space 




Due to limitations of the system, there are some unique features in the data that 
require explanation.  In some instances, the left ventricular pressure drops below 
zero during diastole.  This suction can occur clinically in patients with mitral valve 
stenosis106.  As a mechanical valve is rigid, it can behave similarly to a stenosed 
valve and produce similar suction, depending on the drive pressure of the 
ventricle.  This behavior can also explain the LVP spike in some conditions, as 
the pressure builds up inside the ventricle momentarily between the time the 
mitral and aortic valves open.  Finally, the ringing cause by the mechanical aortic 
valve is visible in the pressure waveforms for both AoP and CdAP.  While this 
makes the calculation of pulse pressures more difficult, it otherwise has no effect 
on the overall results.  
While most of the data agrees with known clinical and literature values, some 
discrepancies do exist.  Some pulse pressures and flows are slightly below 
literature values, which can likely be attributed to operator error.  These values 
can be difficult to attain in real time and are not generated until the full analysis 
is complete.  However, after several rounds of testing and modification, all 
carotid artery flows and pressures generated fell into their target ranges (Table 
5), indicating that the system is indeed capable of generating the necessary 
pressures and flows for the next phase of vessel testing.  
Another interesting observation from the results is the behavior of the pulse 
pressures with increasing VAD flow.  The pulse pressures increase slightly with 
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the introduction of low VAD flow then proceed to drop with increasing VAD flow 
to below their original levels.  An explanation for this trend is that the low VAD 
flow brings the cardiac output back to a normal level, providing the left ventricle 
with enough pressure to generate a normal pulse pressure in the arteries.  
However, as the VAD speed increases and the ventricle is unloaded, this pulse 
pressure slowly dissipates to levels below the initial value.   
One more noteworthy finding from the results is the morphology of the CdAF 
waveform.  While peak and mean CdAF values matched those found in literature, 
as previously discussed, the resulting waveform was visibly less complex than 
the referenced waveform (Figure 27) 88.  The reasoning behind this is the 
limited complexity of the system.  In the end, the available combinations of 
resistors and compliance chambers were unable to perfectly recreate the 
measured waveform and the wave reflections exhibited in a true physiologic 
circulation.  This is most clearly observed when the best fit estimations of both 
literature and obtained CdAF waveforms were plotted (Figure 28).  However, 
with additional testing in the pulsatile VAD, a more accurate waveform may be 
created due to the ability of the VAD pulsatility to create more complex 




Figure 27. Carotid artery waveform in vivo measured via MRI88 
 
Figure 28. Overlay of obtained CdAF waveform versus estimated polynomial 
best fit of literature waveform of CdAF 




























Figure 29. Segment of CdAF waveform in vessel testing during asynchronous 
VAD pulsation at 3200 +/- 800 rpm; cycle time 3.2 seconds 
In conclusion, the benefits of the system certainly outweigh its limitations.  The 
hybrid system integrates an ex vivo perfusion chamber into a mock circulatory 
loop driven by a combination of a mock ventricle and VAD in series.  This allows 
to system to expose any type of vessel to physiologic, pathologic, and VAD-
specific flows and pressures, a feat that is unprecedented in the current 
literature.  With the help of future testing, this system will allow for the collection 
of valuable data on the vascular response to a wide variety of VAD-specific flow 
conditions.  
C. Design Improvements 
The first and simplest design improvement that could be addressed is 
incorporating a thicker plastic tube for the vessel perfusion chamber.  For the 


























current prototype, a 100 mL syringe was used, which has a wall thickness of just 
under 1/16”.  This presented an issue when the three screw-in Luer lock ports 
were inserted into the tubing for fluid exchange and ventilation.  The minimal 
wall thickness required the addition of multiple epoxies and sealants to provide 
enough material for the ports to screw into.  A potential solution would be to use 
plastic PVC pipe of the same inner diameter, but with an increased thickness of 
at least 1/8”.  This would allow the ports to be screwed in to the tubing and 
create a watertight seal without the use of epoxies and sealants that could 
potentially have adverse effects on the biocompatibility of the chamber.  The 
placement of these ports could also be adjusted so that the two ports for 
perfusate circulation are located farther apart to prevent the creation of 
microcurrents during fluid recirculation. 
The main functional flaw with the vessel perfusion chamber prototype was the 
difficulty in attaching the vessel to the two unconstrained and free moving 
plungers, then inserting the system into the tube.  The possibility existed for the 
vessel to become twisted or tear, prompting the need for a design that provides 
a more rigid structure for the cannulated vessel and plungers during reloading 
into the tube.  An additional desired feature was the ability to adjust the length 
of the vessel inside the chamber.  Thus, a screw system similar to that used in a 
syringe pump (Figure 30) was designed.  While one plunger remains stationary, 
the other can be adjusted simply by turning the knob at the end of the threaded 
rod.  O-rings and proper seals should be used to ensure the chamber remained 
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watertight and the entire system was removable from the tube to allow for 
proper vessel loading.  
 
 
Figure 30. Vessel length adjustment system with components: A. rotating knob, 
B. traveling screw element, C. fixed plunger, D. sliding plunger 
 
Another design improvement would be to address one of the main constraints of 
the incubator setup: the inability to properly adjust the height of the fluid 
reservoir.  This controls the preload and has a direct effect on the left ventricular 
end-diastolic pressure.  The lack of adjustability is due to the reservoir being 
contained on the top shelf of the incubator, which is set at a maximum height 
due to the height of the two compliance chambers below.  However, a vacant 
space exists below the top shelf and above the mock ventricle to the side of the 
compliance chambers.  A potential solution to allow some degree of preload 
adjustment is to create a secondary shelf that attaches to the top incubator 
shelf.  The shelf would be half the width of the main incubator shelves so as not 
to interfere with the compliance chambers, and would be suspended from the 
upper shelf by four metal rods that would rise up through the holes in the metal 
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shelf.  The height of the shelf would be adjustable by knobs at the end of each 
rod, thus allowing for the maximal degree of preload adjustability. 
 
D. Future Testing 
This ex vivo vessel perfusion system lays the foundation for a tremendous 
amount of testing on bovine carotid arteries utilizing complex hemodynamic and 
VAD-specific waveforms.  These proposed studies will test the hypothesis that 
diminished pulsatility produced by CF VAD adversely alters vascular function and 
remodeling, which may contribute to the observed clinical complications, as well 
as limit the potential for myocardial recovery.  If substantiated experimentally in 
these studies, flow modulation by varying pump speed (rpm) may provide a 
viable solution.  To test this hypothesis, two specific aims will be completed. 
The first specific aim is to quantify the vascular function of carotid arteries and 
aorta from healthy and heart failure (HF) bovine models in a mock circulation 
system with ex vivo perfusion for 72 hours and compare aortic gene expression 
to human HF patients.  These experiments will utilize the ex vivo vessel perfusion 
system to demonstrate that ex vivo bovine carotid arteries and aortas remain 
viable for up to 72 hours with simulated physiologic flows.  Tissue viability will be 
measured using hematoxylin and eosin (H&E) staining and methyl thiazole 
tetrazolium (MTT) assays.  Arterial contractility, endothelial function, and 
mechanical properties will be quantified for normal and HF animals.  This will be 
accomplished by using flow-mediated dilation techniques, examining pressure-
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diameter-thickness relationships, performing calculations of compliance, using 
vascular tension assays, and comparing clinical gene expression.  
Finally, the second specific aim will test the hypothesis that increased vascular 
pulsatility by flow modulation of rotary blood pumps can restore vascular 
phenotype, structure, and function using the ex vivo perfusion system.  This aim 
will measure arterial responses to CF VAD flow modulation, including 
vasoconstriction, endothelial function, and arterial remodeling via methods 
previously described in the first two specific aims.  Testing will again be 
performed at three VAD speeds in addition to various levels of flow modulation 
using the aforementioned VAD pulsatility program. 
The long-term objective of this testing is to continue to improve HF patient 
outcomes and quality of life by developing safe and effective mechanical support 
strategies for ventricular unloading as well as peripheral targets of the integrated 
HF condition.  While much testing still needs to be performed, the creation of the 
ex vivo vessel perfusion system is the first step in the process.  The system’s 
ability to create hemodynamically complex, VAD-specific waveforms via the 
combination of the mock ventricle and VAD in series in three different 
hemodynamic conditions, while still being small enough to fit in the incubator 
lays a foundation for years of clinically-relevant future experimentation, 
specifically on the influence of pulsatile versus continuous VAD-generated flow 
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002 003 004 005 006 007
baseline modified HF HF, lo VAD HF, med VAD HF, hi VAD HF, full VAD
LVHR 74.672 74.703 74.734 74.679 74.691 74.686 LVHR
LVSV 69.233 53.301 27.455 4.9203 0.00061392 0 LVSV
LVCO 5.1697 3.9817 2.0518 0.36745 4.60E-05 0 LVCO
LVPbd 14.663 11.776 38.08 36.034 34.246 31.908 LVPbd
LVPed 21.063 36.109 20.108 29.645 29.355 19.479 LVPed
LVPpksys 146.81 119.7 134.66 131.52 128.52 121.56 LVPpksys
LVppdPdt 4048.9 3422.7 9829 9401.2 9617.7 9269.1 LVppdPdt
LVpndPdt -3743.1 -3203.3 -9492.7 -9356.2 -9498.6 -9490.6 LVpndPdt
LVEd 0.092439 0.45639 0.1236 1.7087 207.14           NaN LVEd
LVEW 7470.4 3964.8 2130.8 428.35 -0.17921 -0.92132 LVEW
AoPavg 92.155 75.991 81.262 94.963 118.49 148.5 AoPavg
AoPpulse 96.043 83.169 72.974 32.207 18.026 16.662 AoPpulse
AoPsys 167.11 141.32 134.99 115.84 127.69 157.06 AoPsys
AoPdia 71.065 58.152 62.013 83.634 109.66 140.4 AoPdia
AoFavg 4.8139 3.6885 1.7599 0.056954 -0.32597 -0.43026 AoFavg
AoFpulse 23.405 17.111 11.851 3.4949 0.48393 0.37386 AoFpulse
AoFpkpos 18.415 12.608 7.8923 2.0376 -0.05578 -0.22685 AoFpkpos
AoFpkneg -4.9897 -4.5032 -3.9592 -1.4573 -0.53971 -0.60071 AoFpkneg
TPRc 1531.7 1648.8 3697.9 1.39E+05 -29162 -27712 TPRc
CdAPavg 86.329 71.252 75.811 89.237 111.39 139.63 CdAPavg
CdAPmax 149.79 123.35 111.99 104.23 119.24 146.58 CdAPmax
CdAPmin 52.244 41.108 53.612 80.144 103.77 132.88 CdAPmin
LVPavg 57.095 51.451 50.462 50.782 47.435 42.231 LVPavg
LVPmax 146.81 119.7 127.17 131.52 128.52 121.56 LVPmax
LVPmin 4.009 3.1183 -19.922 -22.145 -25.517 -28.72 LVPmin
CdAFavg 0.4558 0.29041 0.32644 0.34437 0.33255 0.46865 CdAFavg
CdAFpkpos 1.045 0.67858 0.79536 0.57406 0.46783 0.65522 CdAFpkpos
CdAFpkneg 0.079613 0.02929 0.072997 0.18039 0.20823 0.30817 CdAFpkneg
CdAFpulse 0.96536 0.64929 0.72237 0.39366 0.2596 0.34705 CdAFpulse
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- Trained in-vitro hemolysis testing for FDA IDE 
and 510K approvals 
Work Experience 
 
 2010 – 2011   Ethicon Endo-Surgery  
     Cincinnati, OH 
Co-op Directors: Kevin Doll, Tony Nguyen, 
Catherine Corbett 
 
- Data analysis using Minitab and Excel 
software 
- Mechanical testing for compressive, tensile, 
and torsional loads 
- Tolerance stack-ups 
- Predictive and applied failure analysis 
- Professional written communication via 
engineering studies 
 
Peer Reviewed Conference Presentations 
 
Slaughter, MS; Sobieski, MA; Buller, MJ; McCants, K; Burkes, E. Single 
Center Experience with Formation of Ring Thrombus on Inlet Bearing with 
Axial Flow Left Ventricular Assist Device. 58th Annual ASAIO Conference, 
San Francisco, CA, 2012. 
 
Buller, MJ; Sobieski, MA; Soucy, KG; Giridharan, GA; Koenig, SC; 
Slaughter, MS. Investigation of myocardial recovery in a chronic ischemic 
heart failure bovine model. 39th Annual ESAO Conference, Rostock, 
Germany, 2012. 
 
Soucy, KG; Ansert, AC; Holley, KP; Spalding, CT; Benzinger, CJ; Buller, 
MJ; Giridharan, GA; Koenig, SC; Sobieski, MA; Slaughter, MS. Feasibility 
of Ventricular-Arterial Cannula for Aortic Valve Bypass. 2012 BMES Annual 
Meeting, Atlanta, GA. 
66 
 
Honors and Awards 
 
1. Dean’s List and Dean’s Scholar 
2. Pi Kappa Alpha Member of the Year, 2012 
3. Tau Beta Pi Engineering Honor Society 
Campus Involvement and Community Service 
  
1. Pi Kappa Alpha fraternity 
2. U of L Dance Marathon 
3. U of L Relay for Life 
4. Alternative Spring Break 
5. Ken-ducky Derby 
6. Prevent Child Abuse America 
7. Make A Wish Foundation 
8. Big Brothers Big Sisters of Kentuckiana 
9. WHAS Crusade for Children 
 
  
  
 
 
 
 
 
 
